Literature DB >> 33636560

Cateslytin abrogates lipopolysaccharide-induced cardiomyocyte injury by reducing inflammation and oxidative stress through toll like receptor 4 interaction.

Carmine Rocca1, Anna De Bartolo2, Fedora Grande3, Bruno Rizzuti4, Teresa Pasqua5, Francesca Giordano6, Maria Concetta Granieri1, Maria Antonietta Occhiuzzi3, Antonio Garofalo3, Nicola Amodio7, Maria Carmela Cerra8, Francis Schneider9, Maria Luisa Panno6, Marie Hélène Metz-Boutigue10, Tommaso Angelone11.   

Abstract

Global public health is threatened by new pathogens, antimicrobial resistant microorganisms and a rapid decline of conventional antimicrobials efficacy. Thus, numerous medical procedures become life-threating. Sepsis can lead to tissue damage such as myocardium inflammation, associated with reduction of contractility and diastolic dysfunction, which may cause death. In this perspective, growing interest and attention are paid on host defence peptides considered as new potential antimicrobials. In the present study, we investigated the physiological and biochemical properties of Cateslytin (Ctl), an endogenous antimicrobial chromogranin A-derived peptide, in H9c2 cardiomyocytes exposed to lipopolysaccharide (LPS) infection. We showed that both Ctl (L and D) enantiomers, but not their scrambled counterparts, significantly increased cardiomyocytes viability following LPS, even if L-Ctl was effective at lower concentration (1 nM) compared to D-Ctl (10 nM). L-Ctl mitigated LPS-induced LDH release and oxidative stress, as visible by a reduction of MDA and protein carbonyl groups content, and by an increase of SOD activity. Molecular docking simulations strongly suggested that L-Ctl modulates TLR4 through a direct binding to the partner protein MD-2. Molecular analyses indicated that the protection mediated by L-Ctl against LPS-evoked sepsis targeted the TLR4/ERK/JNK/p38-MAPK pathway, regulating NFkB p65, NFkB p52 and COX2 expression and repressing the mRNA expression levels of the LPS-induced proinflammatory factors IL-1β, IL-6, TNF-α and NOS2. These findings indicate that Ctl could be considered as a possible candidate for the development of new antimicrobials strategies in the treatment of myocarditis. Interestingly, L-enantiomeric Ctl showed remarkable properties in strengthening the anti-inflammatory and anti-oxidant effects on cardiomyocytes.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antimicrobial peptides; Cardiomyocytes; Cateslytin; Inflammation; Oxidative stress; Toll-like receptor 4

Year:  2021        PMID: 33636560     DOI: 10.1016/j.intimp.2021.107487

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  4 in total

1.  The Catestatin-Derived Peptides Are New Actors to Fight the Development of Oral Candidosis.

Authors:  Davide Mancino; Naji Kharouf; Francesco Scavello; Sophie Hellé; Fouad Salloum-Yared; Angela Mutschler; Eric Mathieu; Philippe Lavalle; Marie-Hélène Metz-Boutigue; Youssef Haïkel
Journal:  Int J Mol Sci       Date:  2022-02-13       Impact factor: 5.923

Review 2.  The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease.

Authors:  Takuya Watanabe
Journal:  Int J Mol Sci       Date:  2021-06-06       Impact factor: 5.923

3.  Catestatin in innate immunity and Cateslytin-derived peptides against superbugs.

Authors:  Francesco Scavello; Angela Mutschler; Sophie Hellé; Francis Schneider; Sylvette Chasserot-Golaz; Jean-Marc Strub; Sarah Cianferani; Youssef Haikel; Marie-Hélène Metz-Boutigue
Journal:  Sci Rep       Date:  2021-08-02       Impact factor: 4.379

4.  The Antioxidant Selenoprotein T Mimetic, PSELT, Induces Preconditioning-like Myocardial Protection by Relieving Endoplasmic-Reticulum Stress.

Authors:  Carmine Rocca; Anna De Bartolo; Maria Concetta Granieri; Vittoria Rago; Daniela Amelio; Flavia Falbo; Rocco Malivindi; Rosa Mazza; Maria Carmela Cerra; Loubna Boukhzar; Benjamin Lefranc; Jérôme Leprince; Youssef Anouar; Tommaso Angelone
Journal:  Antioxidants (Basel)       Date:  2022-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.